Letter/Comment
The latest advocacy letters and comments from the American Hospital Association.
AHA comments on the Centers for Medicare & Medicaid Services’ calendar year 2021 proposed rule for the Home Health prospective payment system (PPS).
AHA to Eli Lilly and Company Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs
AHA expresses profound concern about actions Eli Lilly and Company is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions Sanofi U.S./Sanofi Genzyme are taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions AztraZeneca is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions Novartis Corporation Global, is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions Merck is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
This letter to President Trump offers recommendations for promoting and expanding patients’ telehealth access.
The AHA urges an expeditious review and release of the Physician Self-Referral and Anti-Kickback Statute final regulations that were submitted by the Centers for Medicare & Medicaid Services and the Health & Human Services Office of Inspector General in July.
This letter expresses AHA’s concern about a forthcoming UnitedHealthcare change in coverage policy for laboratory test services.
This letter provides comment on the proposed rule from the Departments of the Treasury, Labor and Health and Human Services that would allow certain grandfathered health plans to increase patient cost-sharing beyond current limits, without losing their grandfathered status.